Baxter, Miromatrix Team Up for Bioengineered Liver

Baxter and Miromatrix Medical began a collaborative research agreement to support further treatment options for patients with acute liver failure (ALF) needing organ support therapies.
 
Miromatrix has made a new liver therapy named miroliverELAP that combines the company’s single-use bioengineered liver with Baxter’s PrisMax system. An IND application for miroliverELAP was submitted to the FDA in November 2022 and aims to begin a Phase I clinical trial using it to treat ALF, following FDA’s decision that the trial can proceed.
 
“Miromatrix believes that miroliverELAPhas the potential to save and improve the lives of ALF patients while simultaneously increasing the availability of livers for transplant into other patients,” Jeff Ross, Ph.D., Miromatrix CEO told the press. “We are excited to be partnering with Baxter to pioneer this next generation innovation in acute care and liver disease.”
 
The liver is capable of regenerating itself back to health in certain circumstances. MiroliverELAP is provides external support to the native liver as a bridge-to-transplant or bridge-to-recovery, potentially helping to avoid a liver transplant.
 
The bioengineered liver is designed to replicate key liver functions and connected to Baxter’s PrisMax continuous renal replacement (CRRT) system outside the body to create the miroliverELAP system. Baxter has also built custom software and disposables to run the miroliverELAP treatments during the Phase I trial.
 
“Baxter is focused on promoting continuous innovation to advance our organ support therapies and further elevate care for patients with ALF and other critical conditions,” said Brian Tufts, VP of Acute Therapies at Baxter. “Combining Miromatrix’s pioneering bioengineered organ technology with Baxter’s expertise in critical care delivery and industry-leading PrisMax system has the potential to transform care for ALF patients.”